Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Direct oral anticoagulant use in special populations
Michelle C. Lamarche
, Eman Alrajhi
, Philip S. Wells
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Direct oral anticoagulant use in special populations'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Advanced Cirrhosis
16%
Advanced Kidney Disease
16%
Anticoagulant Use
100%
Anticoagulants
33%
Antiphospholipid Antibody Syndrome
33%
Cancer Antibodies
16%
Cirrhosis
16%
Comorbidity
33%
Direct Oral Anticoagulants
100%
Efficacy Data
16%
Gastrointestinal Cancer
16%
Genitourinary Cancer
16%
High Risk
16%
Inclusion Criteria
16%
Informed Consent
16%
Kidney Disease Progression
16%
Meta-analysis
16%
National Database
16%
Non-valvular Atrial Fibrillation
33%
Obesity
16%
Patient Demographics
33%
Patient Preference
16%
Pharmacokinetic Data
16%
Phase II Trial
16%
Prospective Randomized Trial
16%
Randomized Controlled Trial
33%
Safety Data
16%
Special Populations
100%
Stroke Prevention
16%
Triple Positive
16%
Venous Thromboembolism
16%
Venous Thromboembolism Treatment
16%
Medicine and Dentistry
Antiphospholipid Antibody
33%
Antithrombotic
33%
Apoplexy
16%
Atrial Fibrillation
33%
Cancer Antibody
16%
Chronic Kidney Disease
16%
Comorbidity
33%
Direct Oral Anticoagulant
100%
Gastrointestinal Cancer
16%
Informed Consent
16%
Liver Cirrhosis
33%
Meta-Analysis
16%
Nephropathy
16%
Patient Population
33%
Patient Preference
16%
Pharmacokinetics
16%
Phase III Trials
16%
Randomized Controlled Trial
33%
Urogenital Tract Cancer
16%
Venous Thromboembolism
33%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
33%
Antiphospholipid Antibody
33%
Atrial Fibrillation
33%
Cancer Antibody
16%
Cerebrovascular Accident
16%
Chronic Kidney Failure
16%
Comorbidity
33%
Digestive System Cancer
16%
Direct Oral Anticoagulant
100%
Kidney Disease
16%
Liver Cirrhosis
33%
Pharmacokinetics
16%
Phase III Trials
16%
Preference
16%
Randomized Controlled Trial
33%
Syndrome
33%
Urogenital Tract Cancer
16%
Venous Thromboembolism
33%